Posted by Michael Wonder on 30 Jun 2022
Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia.
Zanubrutinib is now recommended as an option for the treatment of adults of Waldenström’s macroglobulinaemia who have had at least one treatment, only if they would otherwise have treatment with bendamustine and rituximab.
